Evidence map›Paper›PMID 34403032›Full record

ArticlePharmaceutical research2021

Pharmacokinetics of CuGTSM, a Novel Drug Candidate, in a Mouse Model of Menkes Disease.

Yoshiaki Yamagishi, Toshiyuki Kudo, Masafumi Oyumi, Yusuke Sakamoto, Kazuki Takahashi, Taiki Akashi, Shohei Kobayashi, Takeaki Kawakami, Hitomi Goda, Yasuhiro Sato and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Cuproptosis and Cu: a new paradigm in cellular death and their role in non-cancerous diseases.Apoptosis : an international journal on programmed cell death · 2024
    Review
  3. Early clinical signs and treatment of Menkes disease.Molecular genetics and metabolism reports · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Yoshiaki YamagishiResearch Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan.
Toshiyuki Kudo *Research Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan.
Masafumi OyumiResearch Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan.
Yusuke SakamotoResearch Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan.
Kazuki TakahashiDepartment of Molecular Pharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
Taiki AkashiDepartment of Molecular Pharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
Shohei KobayashiResearch Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan.
Takeaki KawakamiResearch Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan.
Hitomi GodaResearch Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan.
Yasuhiro SatoDepartment of Pediatrics, Teikyo University School of Medicine, Tokyo, Japan.
Masakazu MimakiDepartment of Pediatrics, Teikyo University School of Medicine, Tokyo, Japan.
Hiroko KodamaHealth and Dietetics, Teikyo Heisei University, Graduate School of Health Sciences, Tokyo, Japan.
Mitsutoshi MunakataDepartment of Pediatrics, Tohoku University School of Medicine, Miyagi, Japan.
Kosho MakinoDepartment of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
Hideyo TakahashiDepartment of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
Toshiro FukamiDepartment of Molecular Pharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
Kiyomi ItoResearch Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan. k-ito@musashino-u.ac.jp.
Musashino University · JPMeiji Pharmaceutical University · JPTeikyo University · JPTokyo University of Science · JPTeikyo Heisei University · JPTohoku University · JP

Funding

Japan Society for the Promotion of Science 18K06762
6 · The paper itself

Abstract

purposeMenkes disease is a rare hereditary disease in which systemic deficiency of copper due to mutation of the ATP7A gene causes severe neurodegenerative disorders. The present parenteral drugs have limited efficacy, so there is a need for an efficacious drug that can be administered orally. This study focused on glyoxal-bis (N(4)-methylthiosemicarbazonato)-copper(II (CuGTSM), which has shown efficacy in macular mice, a murine model of Menkes disease, and examined its pharmacokinetics. In addition, nanosized CuGTSM (nCuGTSM) was prepared, and the effects of nanosizing on CuGTSM pharmacokinetics were investigated.

methodsCuGTSM or nCuGTSM (10 mg/kg) was administered orally to male macular mice or C3H/HeNCrl mice (control), and plasma was obtained by serial blood sampling. Plasma concentrations of CuGTSM and GTSM were measured by LC-MS/MS and pharmacokinetic parameters were calculated.

resultsWhen CuGTSM was administered orally, CuGTSM and GTSM were both detected in the plasma of both mouse strains. When nCuGTSM was administered, the C

conclusionAbsorption of orally administered CuGTSM was confirmed in macular mice, and the nano-formulation improved the absorption and retention of CuGTSM in the body. However, the plasma concentration of CuGTSM was lower in macular mice than in control mice, suggesting easier dissociation of CuGTSM.

Indexed as

Administration, OralAnimalsCoordination ComplexesDisease Models, AnimalMaleMenkes Kinky Hair SyndromeMiceMice, Inbred C3HParticle SizeThiosemicarbazonesCoordination Complexesglyoxal-bis(4-methylthiosemicarbazonato)copper(II)ThiosemicarbazonesCopperCuGTSMMacular mouseMenkes diseaseNanosizing

Identifiers

PMID34403032
OpenAlexW3194160126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.